+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Italy Long-Acting Bronchodilator Market 2019-2025

  • ID: 4991495
  • Report
  • January 2020
  • Region: Italy
  • Orion Market Research Private Limited
1 of 3

Enquire about COVID-19 updates for this product.

Enquire Now

FEATURED COMPANIES

  • AstraZeneca PLC
  • GlaxoSmithKline PLC
  • Novartis AG
  • Pulmatrix Inc.
  • ResMed Corp.
  • Savara, Inc.
  • MORE
Italy Long-Acting Bronchodilator Market Size, Share & Trends Analysis Report by Route of Administration (Oral, Nasal, Parenteral, and Inhalation), by Application (Asthma and Chronic Obstructive Pulmonary Disease (COPD)), by End-User (Homecare and Hospitals and Clinics) and Forecast 2019-2025.

Italy long-acting bronchodilator market is anticipated to grow at a substantial rate of 2.5% during the forecast period. The significant prevalence of asthma and COPD has augmented the demand for long-acting bronchodilators within the country. Moreover, rising tobacco smoking activities in the country have also led to the various respiratory disease that has addressed the need for respiratory devices, such as bronchodilators, in the country. In addition, the presence of market players such as Chiesi Farmaceutici S.P.A. in the country is also propelling the market growth. In September 2017, the company completed the clinical study of Tribute with its Trimbow an extra-fine fixed-dose triple combination inhaler. Upon successful commercialization of this long-acting bronchodilator in the country in the near future, the market for the respiratory device such as long-acting bronchodilators will grow.

Italy long-acting bronchodilator market is segmented on the basis of route of administration, application, and end-user. Based on the route of administration, the market is classified into oral, nasal, parenteral, and inhalation. The oral route of administration segment is estimated to contribute to the significant market share in the Italian market over the forecast period. Moreover, on the basis of application, the market has been classified into asthma and COPD diseases. The asthma disease application segment dominated the regional market in 2018 and is further estimated to follow the same trend over the forecast period. This is mainly due to the high prevalence of asthma in the country.

Furthermore, the market is characterized by the presence of several manufacturers that are developing and providing long-acting bronchodilator to cater to a wide range of customers within and outside the country. The major players of the Italy long-acting bronchodilator market include Chiesi Farmaceutici S.P.A., Boehringer Ingelheim International GmbH, AstraZeneca PLC, GlaxoSmithKline PLC, Novartis AG, Teva Pharmaceuticals Industries Ltd. These players adopt various strategies to capitalize on market growth opportunities. Mergers and acquisitions, product launch, geographical expansion, partnerships, and collaborations are the majorly adopted strategies by the market players.

Research Methodology

The market study of the Italy long-acting bronchodilator market is incorporated by extensive primary and secondary research conducted by the research team. Secondary research has been conducted to refine the available data to breakdown the market in various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macro-economic factors.

Numbers extracted from secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings the authenticity of our reports.

Secondary Sources Include:
  • Financial reports of companies involved in the market
  • Whitepapers, research-papers, and news blogs
  • Company websites and their product catalog
The report is intended for long-acting bronchodilator manufacturers, contract research organizations (CROs), healthcare sector, market research firms, and government organizations, for overall market analysis and competitive analysis. The report provides an in-depth analysis of the market size and growth opportunities. The report will serve as a source for 360-degree analysis of the market thoroughly delivering insights into the market for making better business decisions.

Market Segmentation:
1. Italy Long-Acting Bronchodilator Market Research and Analysis by Route of Administration
2. Italy Long-Acting Bronchodilator Market Research and Analysis by Application
3. Italy Long-Acting Bronchodilator Market Research and Analysis by End-User
The Report covers:
  • Comprehensive research methodology of the Italy long-acting bronchodilator market.
  • This report also includes a detailed and extensive market overview with key analyst insights.
  • An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
  • Analysis of regional regulations and other government policies impacting the Italy long-acting bronchodilator market.
  • Insights about market determinants which are stimulating the Italy long-acting bronchodilator market.
  • Detailed and extensive market segments with regional distribution of forecasted revenues.
  • Extensive profiles and recent developments of market players.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • AstraZeneca PLC
  • GlaxoSmithKline PLC
  • Novartis AG
  • Pulmatrix Inc.
  • ResMed Corp.
  • Savara, Inc.
  • MORE
1. Report Summary
1.1. Research Methods and Tools
1.2. Market Breakdown
1.2.1. By Segments

2. Market Overview and Insights
2.1. Scope of the Report
2.2. Analyst Insight & Current Market Trends
2.2.1. Key Findings
2.2.2. Recommendations
2.2.3. Conclusion
2.3. Rules & Regulations

3. Competitive Landscape
3.1. Company Share Analysis
3.2. Key Strategy Analysis
3.3. Key Company Analysis
3.3.1. Overview
3.3.2. Financial Analysis
3.3.3. SWOT Analysis
3.3.4. Recent Developments

4. Market Determinants
4.1. Motivators
4.2. Restraints
4.3. Opportunities

5. Market Segmentation
5.1. Italy Long-Acting Bronchodilator Market by Route of Administration
5.1.1. Oral
5.1.2. Nasal
5.1.3. Parenteral
5.1.4. Inhalation
5.2. Italy Long-Acting Bronchodilator Market by Application
5.2.1. Asthma
5.2.2. Chronic Obstructive Pulmonary Disease (COPD)
5.3. Italy Long-Acting Bronchodilator Market by End-User
5.3.1. Homecare
5.3.2. Hospitals and Clinics

6. Company Profiles
6.1. Adamis Pharmaceuticals Corp.
6.2. AstraZeneca PLC
6.3. Boehringer Ingelheim International GmbH
6.4. Chiesi Farmaceutici S.P.A.
6.5. GlaxoSmithKline PLC
6.6. Novartis AG
6.7. Pulmatrix Inc.
6.8. ResMed Corp.
6.9. Savara, Inc.
6.10. Sunovion Pharmaceuticals
6.11. Teva Pharmaceuticals Industries Ltd.
6.12. Vitalograph Ltd.
Note: Product cover images may vary from those shown
3 of 3
  • Adamis Pharmaceuticals Corp.
  • AstraZeneca PLC
  • Boehringer Ingelheim International GmbH
  • Chiesi Farmaceutici S.P.A.
  • GlaxoSmithKline PLC
  • Novartis AG
  • Pulmatrix Inc.
  • ResMed Corp.
  • Savara, Inc.
  • Sunovion Pharmaceuticals
  • Teva Pharmaceuticals Industries Ltd.
  • Vitalograph Ltd.
Note: Product cover images may vary from those shown
Adroll
adroll